Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free SCPS Stock Alerts

Scopus BioPharma (SCPS) Competitors

Scopus BioPharma logo
$0.0005 0.00 (0.00%)
As of 07/24/2026
Compare

SCPS vs. VINC, CLVR, VRPX, TRVN, and NAVB

Should you buy Scopus BioPharma stock or one of its competitors? MarketBeat compares Scopus BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scopus BioPharma include Vincerx Pharma (VINC), Clever Leaves (CLVR), Virpax Pharmaceuticals (VRPX), Trevena (TRVN), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

How does Scopus BioPharma compare to Vincerx Pharma?

Vincerx Pharma (NASDAQ:VINC) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Scopus BioPharma's return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Scopus BioPharma N/A N/A N/A

In the previous week, Vincerx Pharma had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Vincerx Pharma and 0 mentions for Scopus BioPharma. Vincerx Pharma's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Scopus BioPharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

44.0% of Vincerx Pharma shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vincerx Pharma has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

Summary

Vincerx Pharma beats Scopus BioPharma on 4 of the 7 factors compared between the two stocks.

How does Scopus BioPharma compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Clever Leaves has a beta of 3816.13, indicating that its stock price is 381,513% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Scopus BioPharma N/A N/A N/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Scopus BioPharma Neutral

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Scopus BioPharma has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Summary

Clever Leaves beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Scopus BioPharma compare to Virpax Pharmaceuticals?

Scopus BioPharma (NASDAQ:SCPS) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Virpax Pharmaceuticals Neutral

Scopus BioPharma's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

Scopus BioPharma has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -16.52, suggesting that its share price is 1,752% less volatile than the broader market.

Summary

Scopus BioPharma beats Virpax Pharmaceuticals on 5 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Trevena?

Trevena (NASDAQ:TRVN) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Scopus BioPharma has lower revenue, but higher earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Trevena has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

13.6% of Trevena shares are held by institutional investors. 2.7% of Trevena shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Trevena Neutral
Scopus BioPharma Neutral

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Scopus BioPharma N/A N/A N/A

Summary

Trevena and Scopus BioPharma tied by winning 3 of the 6 factors compared between the two stocks.

How does Scopus BioPharma compare to Navidea Biopharmaceuticals?

Scopus BioPharma (NASDAQ:SCPS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Scopus BioPharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Scopus BioPharma has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Navidea Biopharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

Get Scopus BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCPS vs. The Competition

Export
MetricScopus BioPharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$21K$975.85M$6.87B$12.26B
Dividend YieldN/A4.84%2.67%9.79%
P/E RatioN/A1.5327.1423.64
Price / SalesN/A104.46517.0889.45
Price / CashN/A20.0650.5459.64
Price / BookN/A8.4710.286.07
Net Income-$11.61M-$2.70M$3.60B$331.99M
7 Day PerformanceN/A-2.29%-1.27%-0.63%
1 Month PerformanceN/A-3.97%-0.37%-2.00%
1 Year PerformanceN/A27.39%18.30%13.62%

Scopus BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCPS
Scopus BioPharma
N/A$0.00
flat		N/A+66.7%$21KN/AN/A9
VINC
Vincerx Pharma
N/A$0.02
+18.9%		N/AN/A$79KN/AN/A60
CLVR
Clever Leaves
N/A$0.01
flat		N/A+3,250.0%$18K$17.42MN/A560
VRPX
Virpax Pharmaceuticals
N/A$0.01
flat		N/A-99.5%$14KN/AN/A7
TRVN
Trevena
N/A$0.01
flat		N/A-98.8%$11K$443KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SCPS) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel